NEW YORK, July 3 – Roche Diagnostics has entered into a 15-year agreement to purchase, use and resell CombiMatrix’s biochips, the companies announced Tuesday.
The worldwide, non-exclusive deal includes minimum payments by Roche to CombiMatrix during the first three years of the agreement, including royalties, payments for products, and R&D projects. The deal also stipulates that the companies develop a joint platform technology for standardized biochips.
Financial details of the agreement were not disclosed.
“This unique platform will be useful for multiple applications, including gene expression studies, single nucleotide polymorphism analysis, disease classification, pathway identification, and toxicology studies, Susanne Raehs, head of Roche Applied Science, said in a statement.
Acacia Research is the majority owner of Snoqualmie, Wash.-based CombiMatrix, which uses semiconductor technology to develop customizable microarrays. CombiMatrix remains registered for an initial public offering filed in November.